The role of a model is one many people would like to take on, but understanding the role and physical requirements is often something of a mystery for those who are outside the industry or trying to break into it. Although the specific numbers given in this article are based on the requirements of runway models it is important to remember the different forms of modeling available often have specific requirements that differ from those given below. It is always a good idea to get fit if you want to become a model, but being completely ripped with muscle is not always the best way forward for those looking to enter the fashion industry.
A good starting point for those looking to enter the fashion industry is to get some advice from a high quality modeling agency, which could include The Brown Agency of Austin, Texas that is one of the world’s best known agencies. The agency arrived in Austin in 2010 in a bid to expand the number of models from across the U.S. working in various styles of modeling.
Sometimes the move of an individual into the modeling industry comes after they are spotted by an industry professional, if a photographer or talent contacts an individual it is always a good idea to check them out with a group like The Brown Agency. The Brown Agency publicizes their models work online through their Website, which is divided into different areas for clients to look over.
For female models the requirements for becoming a fashion model include the need to have a tall and slender frame, which should see the individual model be at least 5’8″ and extend to around 5’11”; any smaller or taller than this and the clothes being modeled are often seen as not looking correct on the individual.
Male models also have specific requirements the fashion industry usually demands, including a height of between six feet and 6’2″; for men the chest size is all important and should be somewhere between 40 and 42 inches. It is important to remember each model will work in niche areas of the industry that may have difference requirements than those of the runway.
Seattle Genetics is an innovative biotechnology firm based in Seattle, Washington. They focus on creative cancer treatments utilizing empowered monoclonal antibodies. They are best known for creating a specific type of empowered monoclonal antibody called ADC, or Antibody Drug Conjugates. ADCs are molecules that consist of both an antibody and anti-cancer substance. These treatments pinpoint cancer cells more precisely, preventing damage to healthy cells that is associated with other treatment modalities.
Seattle Genetics’ best known product is an ADC called Adcetris, a treatment for Hodgkin’s Lymphoma. Due to its impressive efficacy, it was fast-tracked for approval by the FDA in 2011. Approved for use in Europe and Australia, Adcetris is in use worldwide. In addition to Adcetris, Seattle has cooperated with a host of companies to produce other treatments. These partnerships have yielded revenues of nearly a billion dollars for the relatively new company.
Seattle Genetics Co-Founder Appointed to Board of Directors for Mirna Therapeutics Inc.
The company was co-founded in 1988 by Clay Siegall, a distinguished researcher who had previously worked at Bristol-Myers Squibb and the National Institutes of Health. He serves as the President, CEO, and Chairman of the Board of Directors. Siegall secured hundreds of millions of dollars in funding and led the company to its IPO in 2001. In addition to heading up Seattle Genetics, Siegall is on the board of directors of several major biotechnology companies and research organizations.
The Bothell, Washington based drug firm Seattle Genetics has unveiled an ambitious plan to expand its drug business and increase the size of its workforce. According to an excerpt published in theBizjournals.com, the fast growing cancer drug maker plans to widen the reach of its only commercialized cancer drug, Adcetris and hire 100 new workers. The company CEO, Clay Siegall told Bizjournals that there are ongoing clinical trials to test Adcetris on the treatment of various types of lymphomas.
In 2015, the company made a staggering $226 million from sales of the drug in the US and Canada. Sales in the two North American countries are expected to rise to about $265 million in 2016 as the company looks to ramp up its overseas sales through its marketing partner, Takeda Pharmaceutical. Seattle Genetics has already initiated a capital intensive phase 3 trials to check the viability of treating newly diagnosed Hodgkin lymphoma and other related conditions using Adcetris.
The company also hopes to unveil 12 new drugs it has been developing on the sidelines of Adcentric. The drugs on trials include 33A for treating acute myeloid leukemia and drugs for treating and managing bladder and breast cancer. Seattle Genetics will also hire 100 new workers in its US office and an additional 20 to work in its Switzerland outpost. The move will bring the number of employees working for the company to close to 1000.
About Clay Siegall
Dr. Clay Siegall is the CEO and Co-Founder of Seattle Genetics biotech company. According to Siegall’s LinkedIn account, the firm was established in 1998 on a strong foundation of continued research, scientific innovation, passion to help patients and steady drug development pathway. Through Siegall’s stellar leadership, Seattle Genetics has become a leader in the development of antibody-drug conjugates (ADC)drugs.
The company has strategic working licenses with a number of companies including Pfizer and GlaxoSmithKline to promote the ADC technology. Siegall holds a Ph.D. in Genetics from George Washington University and a BSc in Zoology from University of Maryland.